TG Therapeutics, Inc.
TGTX
$28.62
$0.662.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 87.32% | 100.88% | 30.96% | 33.54% | 40.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.32% | 100.88% | 30.96% | 33.54% | 40.80% |
| Cost of Revenue | 161.70% | 152.01% | 135.86% | 159.60% | 172.34% |
| Gross Profit | 77.47% | 94.11% | 22.77% | 24.83% | 32.34% |
| SG&A Expenses | 50.38% | 42.16% | 36.09% | 31.60% | 25.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.72% | 61.75% | 50.37% | 35.52% | 34.76% |
| Operating Income | 194.13% | 20,452.28% | -15.71% | 23.71% | 103.21% |
| Income Before Tax | 319.59% | 731.98% | -30.98% | 0.30% | 95.94% |
| Income Tax Expenses | -15,468.11% | -75,198.75% | 6,109.89% | 518.14% | 466.92% |
| Earnings from Continuing Operations | 1,812.41% | 3,215.24% | -36.82% | -4.97% | 84.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,812.41% | 3,215.24% | -36.82% | -4.97% | 84.52% |
| EBIT | 194.13% | 20,452.28% | -15.71% | 23.71% | 103.21% |
| EBITDA | 193.79% | 25,302.45% | -15.80% | 23.37% | 101.48% |
| EPS Basic | 1,803.34% | 3,184.55% | -38.32% | -6.17% | 100.50% |
| Normalized Basic EPS | 319.08% | 724.42% | -32.61% | -0.94% | 112.69% |
| EPS Diluted | 1,928.26% | 2,540.56% | -37.96% | 10.97% | 1,308.25% |
| Normalized Diluted EPS | 334.69% | 626.01% | -31.90% | 16.48% | 823.08% |
| Average Basic Shares Outstanding | 0.09% | 0.85% | 1.19% | 1.41% | 2.38% |
| Average Diluted Shares Outstanding | 3.05% | 6.09% | 6.90% | 9.63% | 7.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |